Cargando…

Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trial

Locoregional radiotherapy added to chemotherapy has significantly improved survival in de novo metastatic nasopharyngeal carcinoma (mNPC). However, only 54% of de novo mNPC patients who received sequential chemoradiotherapy have complete or partial response 3 months after radiotherapy. This Simon’s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Si-Yuan, Duan, Xiao-Tong, Li, Hui-Feng, Peng, Lan, Wang, Zhi-Qiang, Xu, Gui-Qiong, Hua, Yi-Jun, Zou, Xiong, You, Rui, Ouyang, Yan-Feng, Liu, You-Ping, Gu, Chen-Mei, Yang, Qi, Jiang, Rou, Zhang, Meng-Xia, Lin, Mei, Xie, Yu-Long, Lin, Chao, Ding, Xi, Xie, Ruo-Qi, Duan, Chong-Yang, Zhang, Wei-Jing, Huang, Pei-Yu, Chen, Ming-Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694661/ https://www.ncbi.nlm.nih.gov/pubmed/37951218 http://dx.doi.org/10.1016/j.xcrm.2023.101279

Ejemplares similares

Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial
por: Hua, Yijun, et al.
Publicado: (2021)

Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
por: Ding, Xi, et al.
Publicado: (2023)

Efficacy of local therapy to metastatic foci in nasopharyngeal carcinoma: large-cohort strictly-matched retrospective study
por: Zhang, Meng-Xia, et al.
Publicado: (2022)

Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial
por: Chen, Jie, et al.
Publicado: (2022)

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
por: Wang, Feng-Hua, et al.
Publicado: (2021)

Severe cumulative skin toxicity during toripalimab combined with vemurafenib following toripalimab alone
por: Zhou, Hong, et al.
Publicado: (2023)

Fosaprepitant Weekly vs Every 3 Weeks for the Prevention of Concurrent Chemoradiotherapy–Induced Nausea and Vomiting: A Pilot Randomized Clinical Trial
por: Yang, Qi, et al.
Publicado: (2023)

Biopsy of distant metastasis is not a significant prognostic factor for synchronous metastatic nasopharyngeal carcinoma: a propensity score-matched analysis from the Surveillance Epidemiology and End-Results Registry
por: Lin, Mei, et al.
Publicado: (2021)

A curative-intent endoscopic surgery for postradiation nasopharyngeal necrosis in patients with nasopharyngeal carcinoma
por: Zou, Xiong, et al.
Publicado: (2018)

Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer
por: Zhao, Ze-Rui, et al.
Publicado: (2021)

Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up
por: You, Rui, et al.
Publicado: (2017)

Concurrent Chemoradiotherapy With or Without Induction Chemotherapy for Patients with Stage II Nasopharyngeal Carcinoma: An Update
por: Jin, Ting, et al.
Publicado: (2019)

Addition of chemoradiotherapy to palliative chemotherapy in de novo metastatic nasopharyngeal carcinoma: a real-world study
por: Zheng, Shuo-Han, et al.
Publicado: (2022)

A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)
por: Chen, Rui, et al.
Publicado: (2023)

Neoantigen landscape in metastatic nasopharyngeal carcinoma
por: Lin, Mei, et al.
Publicado: (2021)

The Changing Therapeutic Role of Chemo-radiotherapy for Loco-regionally Advanced Nasopharyngeal Carcinoma from Two/Three-Dimensional Radiotherapy to Intensity-Modulated Radiotherapy: A Network Meta-Analysis
por: You, Rui, et al.
Publicado: (2017)

Induction chemotherapy with sequential nimotuzumab plus concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma: A retrospective real-world study
por: Jiang, Danxian, et al.
Publicado: (2023)

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients with cervical nodal necrosis
por: Lan, Mei, et al.
Publicado: (2017)

Toripalimab-Induced Dermatomyositis in a Patient with Metastatic Melanoma
por: Lin, Jingrong, et al.
Publicado: (2020)

Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab
por: Zhou, Huanyu, et al.
Publicado: (2022)

Flat dose regimen of toripalimab based on model-informed drug development approach
por: Li, Lili, et al.
Publicado: (2023)

Toripalimab in advanced biliary tract cancer
por: Li, Wei, et al.
Publicado: (2022)

Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma
por: Xu, Yu-Jie, et al.
Publicado: (2021)

The clinical prognostic value of PD-L1 after concurrent chemoradiotherapy in Chinese nasopharyngeal carcinoma patients
por: Long, Guoxian, et al.
Publicado: (2021)

Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma
por: Zong, Jing-Feng, et al.
Publicado: (2021)

Multisystem immune-related adverse events due to toripalimab: Two cases-based review
por: Chen, Yanran, et al.
Publicado: (2022)

Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study
por: Ding, Xi, et al.
Publicado: (2023)

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021)

Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients
por: Chen, Jinzhang, et al.
Publicado: (2020)

Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin
por: Zeng, Zhen, et al.
Publicado: (2018)

Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in the treatment of different risk locoregionally advanced nasopharyngeal carcinoma
por: Liu, Li-Ting, et al.
Publicado: (2020)

Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinoma
por: Liu, You-Ping, et al.
Publicado: (2019)

Effects of intensity-modulated radiotherapy and chemoradiotherapy on attention in patients with nasopharyngeal cancer
por: Wei, Qing, et al.
Publicado: (2017)

Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial
por: Wen, Zhenyu, et al.
Publicado: (2023)

The impact of smoking on the clinical outcome of locoregionally advanced nasopharyngeal carcinoma after chemoradiotherapy
por: Guo, Shan-Shan, et al.
Publicado: (2014)

A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy: a matched study
por: Meng, Dong-Fang, et al.
Publicado: (2018)

Genetic Variations in Radiation and Chemotherapy Drug Action Pathways and Survival in locoregionally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy
por: Liu, Huai, et al.
Publicado: (2013)

Evolutionary route of nasopharyngeal carcinoma metastasis and its clinical significance
por: Lin, Mei, et al.
Publicado: (2023)

Sequential induction chemotherapy plus intensity‐modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three‐year report of a phase II, single center, randomized, non‐inferiority trial
por: Yang, Zhining, et al.
Publicado: (2021)

Development and prospective validation of a risk score model in guiding individualized concurrent chemoradiotherapy in stage II nasopharyngeal carcinoma in intensity‐modulated radiotherapy era
por: Yang, Shan‐Shan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e2na8b0mjhnm1134ii7uvqboad